[
    {
        "utterance": "Faranak Fattahi: third point stem cells of the peripheral nervous system, particularly the enteric nervous system, and we're interested in figuring out how these different enteric neurons and glia within these organoids are affected in disease. So in the gut those would be motility diseases that you know, lead to abnormalities in movement of the gut tube and the muscle tissue. We're also interested in figuring out how neurological diseases like Parkinson's and Alzheimer's and other neurodegenerative diseases manifest in the enteric nervous system. So, this is a brief overview. ",
        "annotations": {
            "develop idea": "The speaker expands on their research interest by specifying the types of diseases they are interested in.",
            "clarify goal": "The speaker defines their research goals and interests."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you. That was that was great. Erin. ",
        "annotations": {
            "acknowledge contribution": "verbally recognizes another group member's input",
            "supportive response": "Expressing agreement, validation, or positive evaluation for other group members' contributions"
        }
    },
    {
        "utterance": "Erin Longbrake: Hi, I'm Erin Longbrake. I'm at Yale. I'm a neuroimmunologist. My research is mainly in multiple sclerosis, um, and I'm interested in detecting the disease before it has caused damage to the nervous system. So I'm interested in the microbiome both as something that might facilitate some of the genetic environmental interactions that lead to the immune disregulation of MS. I'm also interested in in it as a biomarker of something that may be able to help us detect um, when something first starts to go awry that ultimately would lead to autoimmunity. Um, so that's my general interests. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their own expertise or qualifications related to the task, mentioning they are a neuroimmunologist and their research is mainly in multiple sclerosis."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. Thank you. Pamela. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input.",
            "supportive response": "The speaker is expressing agreement and validation for other group members' contributions."
        }
    },
    {
        "utterance": "Pamela Chang: Hi, my name is Pamela Chang and I'm an assistant professor at Cornell in Ithaca. Um, my lab is interested in developing chemical tools to characterize or study the metabolism of the gut microbiome. And we also look at small molecule metabolites that bacteria in the gut make and how that modulates host immune responses in inflammatory diseases and also in an infection. ",
        "annotations": {
            "signal expertise": "The speaker is stating their position (assistant professor at Cornell) and their research focus, which indirectly signals their expertise.",
            "develop idea": "The speaker is elaborating on their research focus, providing details about their lab's interests."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. Thank you. ",
        "annotations": {
            "acknowledge contribution": "The speaker is verbally recognizing another group member's input.",
            "supportive response": "The speaker is expressing a positive evaluation for other group members' contributions."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Um, uh Leon? Ilian? ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: How do you pronounce your name? How do you say your name? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on how to pronounce Iliyan Iliev's name."
        }
    },
    {
        "utterance": "Iliyan Iliev: Ilian. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Ilian. Okay, sorry. ",
        "annotations": {
            "process management": "The speaker is managing the interpersonal dynamics of the meeting by correcting the pronunciation of a participant's name and apologizing, which helps in smooth communication."
        }
    },
    {
        "utterance": "Iliyan Iliev: Hi, so uh I'm a associate professor in Wild Cornell Medicine, which is the medical campus of Cornell University here in uh New York City. Uh my lab is immunology lab, but we are very interested in the microbiota and more specifically in the fungal microbiota. Uh so in the area of uh of neuroimmunology that came in the lab with the observation that uh specific fungi and their metabolites can actually ramp up a signaling which turned out to be through a cytokine called L17 uh and uh the receptors expressed in neurons and that modulates behavior. So that's some uh direction that we are pursuing right now. And we are looking in patients populations how that is working and how polymorphisms and loss of function mutations are affecting those phenotypes. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his position as an associate professor and mentions his lab's focus, indicating his expertise.",
            "develop idea": "The speaker is elaborating on his lab's research interests and specific areas of focus within immunology and neuroimmunology."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. We're looking at fungi also on our new treatment. So, um Oh nice. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a previous speaker's contribution with 'That's great.'",
            "develop idea": "The speaker develops the idea by sharing their own research related to fungi and a new treatment.",
            "express humor": "The speaker ends with 'Oh nice,' which can be seen as a mildly positive or humorous expression."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, we we just had like one study that came up and we are following up on that. So it's kind of very interesting. ",
        "annotations": {
            "express humor": "The speaker makes a somewhat casual comment about something being 'kind of very interesting,' which can be seen as a light or humorous way to express interest."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Again, so I'm happy to talk about that later if you want. All right, great. Um, so Tom. ",
        "annotations": {
            "encourage participation": "Rosa invites Tom to contribute by saying 'so Tom', encouraging him to share his thoughts or information."
        }
    },
    {
        "utterance": "Tom Mansell: Hi, Tom Mansell. I am in uh chemical and biological engineering at Iowa State University. Our interest is in the microbiome as an ecosystem where uh that's that's going to be harsh to our bug of interest, which is a live biotherapeutic. So our goal is to secrete small molecules or peptides or proteins in situ in the gut and in order to do that, obviously it has to thrive in this very competitive environment and be able to do its job, which is secretion of the of the therapeutic. And so we're really interested in we do genome engineering to look at the genes that affect survival phenotypes of these bacteria and we're also interested in the um access between prebiotics uh and uh and the growth of these bugs in this environment. So we're really interested in engineered uh synbiotics where we take prebiotics and mix them with probiotics and uh improve their overall outcomes. ",
        "annotations": {
            "propose new idea": "The speaker introduces his research interests and goals, which can be considered as proposing new ideas or areas of study.",
            "signal expertise": "The speaker mentions his department and university, signaling his background.",
            "clarify goal": "The speaker defines his research objectives and interests."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you. Uh, Melanie. ",
        "annotations": {
            "acknowledge contribution": "Rosa Krajmalnik-Brown is thanking someone, which acknowledges their contribution.",
            "encourage participation": "By saying 'Uh, Melanie.', Rosa Krajmalnik-Brown is inviting or encouraging Melanie to participate."
        }
    },
    {
        "utterance": "Melanie Gareau: Um, I'm Melanie Gareau. I'm an associate professor at the Vet school at UC Davis. Um, and my lab's interested in looking at the development of the microbiota gut brain axis, so how colonization impacts maturation of the gut and how that's reflected in changes in our development and behavior in adulthood. Um, I'm a GI physiologist by training and uh we're really interested how this connects with um pediatric IBD and overall IBD in adulthood. ",
        "annotations": {
            "signal expertise": "Melanie Gareau explicitly states her position, training, and her lab's interests.",
            "clarify goal": "Melanie Gareau is defining her lab's objectives and interests."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. So I put the question in the, I don't know if you guys see the in the chat. I put the topic for our conversation. But before we start taking the conversation, I need someone to volunteer to be a scribe. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by requesting a volunteer to be a scribe, which is an example of organizing group activities."
        }
    },
    {
        "utterance": "Erin Longbrake: I can do it. Um where are we supposed to type notes though? Was there a Google document somewhere or ",
        "annotations": {
            "ask question": "Erin is requesting information about where to type notes, indicating a question about the process.",
            "process management": "Erin is seeking information about the process of taking notes, which relates to managing the meeting's flow."
        }
    },
    {
        "utterance": "Andrew Feig: There is a word doc that if you go into the Google Drive, do you have are you in the Google Drive? I'm in the Google Drive, yeah. Uh go into the virtual meeting materials. Yep. The the ultimate PowerPoint slide is at the very bottom. Syllog MD 2022 meeting slides. Yeah. And then there's a raw notes from breakout sessions folder. If you go in there, each breakout session has a raw notes that you you can just freehand just uh ",
        "annotations": {
            "Process Management": "Andrew Feig is guiding the group on how to access necessary documents for the meeting, thereby managing the meeting flow.",
            "Assign Task": "Although indirectly, Andrew Feig's instructions support Erin Longbrake in her role as a scribe by providing her with the necessary access to documents."
        }
    },
    {
        "utterance": "Erin Longbrake: We're 1.4. ",
        "annotations": {
            "process management": "Erin is confirming their status or location in the meeting materials."
        }
    },
    {
        "utterance": "Andrew Feig: Yep. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Okay, thanks. All right, I'm I'm good. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a simple acknowledgment and confirmation of readiness."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Barriers affecting the gut brain axis. That's the topic. And I just put on the comments box um the description of our breakout session and I can maybe start with um asking questions and see who wants to start answering. So are permeability changes linked or correlated to um the gut brain axis and yeah, the the blood brain barrier and the intestinal barrier and the mucocil barrier um and how they're altered during um disease states. Hold on one second, I need to close my door. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the topic by asking about permeability changes linked to the gut brain axis and barriers.",
            "process management": "The speaker is managing the discussion process by suggesting how they will proceed with asking questions."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I apologize for that. ",
        "annotations": {
            "process management": "Managing the meeting environment by apologizing for a brief interruption to close her door."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: All right, Erin, are you ready? ",
        "annotations": {
            "ask question": "The speaker is requesting information or confirmation from Erin about her readiness.",
            "encourage participation": "The speaker is directly involving Erin in the conversation, inviting her to participate."
        }
    },
    {
        "utterance": "Erin Longbrake: Yep, I'm I'm good. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah. So we have great expertise in this panel because we have people that are focused on um the chemicals, organoids, the gut, the brain, immunology, so um I I expect great discussion about this. So who wants to get started? ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute to the discussion by asking, 'So who wants to get started?'",
            "process management": "The speaker transitions the meeting from introduction to the discussion phase."
        }
    },
    {
        "utterance": "Faranak Fattahi: So I can maybe like start. Um, you know, thinking about the enteric nervous system, um, and how the neurons in the gut regulate the tissue homeostasis. I know they play an important role in uh the the epithelial barrier. And so if you have inflammatory conditions that affect the neurons or in some uh developmental defects if the nerves are not developed properly or the tissues as they call it aganglionic, the epithelium becomes leaky then that then leads to more inflammation and more damage to the nerves and this cascade this perpetual cascade of tissue inflammation and breakdown. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new perspective on the enteric nervous system's role in tissue homeostasis.",
            "develop idea": "The speaker elaborates on the role of neurons in the gut in regulating tissue homeostasis and provides examples of the effects of inflammatory conditions or developmental defects."
        }
    },
    {
        "utterance": "Iliyan Iliev: So so in humans, there are direct uh correlations. So we went after some of those genetically, right? So you go actually and you target pathways that are involved in uh in tight junction and uh in uh pathways that are indirectly actually uh correlated to barriers. And that and then if you have actually microbial trigger, you can affect directly the uh blood brain barrier. So uh the question now is uh so so once you come up uh come up with a driver and then a trigger, the question is like uh to what extent it's uh it's really affected and then uh if that will leave lead to uh any physiology. So that's something that we are trying to explore and like how big is that uh change and you can go with different particles and so on, you can figure out uh what size molecules can actually get into the brain, right? Which is important as well. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by providing more details and explanations about the relationship between microbial triggers and the blood-brain barrier.",
            "ask question": "The speaker poses questions about the extent of the effect of microbial triggers on physiology and the size of molecules that can affect the brain."
        }
    },
    {
        "utterance": "Jilyan Iliev, WCM, Cornell University: working that area and to kind of follow up. Uh, so if you guys because we are very new, you know, I worked a lot on the gut barrier but not the blood brain barrier. So we are applying a lot of knowledge like that, but uh, I'm not sure what is the best literature. I I did a lot of research on that but couldn't really find the best one that will address the question about how big molecules can go depending on your genetic defect. ",
        "annotations": {
            "identify gap": "The speaker expresses uncertainty about the best literature on the blood-brain barrier and its relation to genetic defects, indicating a gap in their knowledge.",
            "acknowledge contribution": "The speaker mentions their previous work on the gut barrier and how it relates to the current discussion, acknowledging their contribution to the field."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Would the molecule need to be appropriately sized though? I mean, in a sense, if you have inflammatory mediators that are within the bloodstream, they could impact the endothelium and create leakiness that would be independent of the size of the molecule because once you've broken down the barrier then large molecules can pass too. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on a prior statement.",
            "develop idea": "The speaker is expanding and elaborating on existing ideas through reasoning and examples."
        }
    },
    {
        "utterance": "Jilyan Iliev, WCM, Cornell University: They can, but then uh, the other question is uh, you know, some of those uh, susceptibilities or those uh, defects in the barrier you cannot uh, really uncover until you have the proper trigger. So sometimes the trigger is not known. So you have to actually really come up with a system where you predict triggers because if you do it genetically in different mouse models that can be huge in their price, right? You it's not a lab, it's kind of a company that has to do it. But if you can predict, then you can then go by size because some of those things will be not specific but others will be. So I don't know, that's my thinking there but uh. ",
        "annotations": {
            "Develop idea": "The speaker is expanding on previous ideas or discussions, providing more detail and considerations about the challenges of identifying susceptibilities or defects in barriers without a proper trigger.",
            "Ask question": "The speaker poses a rhetorical or discussion-inviting consideration, 'So I don't know, that's my thinking there but uh', which invites further discussion or input.",
            "Offer feedback": "The speaker provides thoughts on the approach to studying barriers and triggers, offering considerations for how to proceed with research in this area."
        }
    },
    {
        "utterance": "Faranak Fattahi, UCSF: Are there in vitro models that are more scalable for screening through uh molecules that are permeable or unpermeable through the blood brain barrier? Or you know how pharma companies used to like test drug permeability, so some of those might be useful for microbial metabolites as well. I'm not sure if any screens in this uh realm has been done before or the models good enough for these types of studies. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the existence of in vitro models for screening molecule permeability through the blood-brain barrier.",
            "develop idea": "The speaker briefly elaborates on the idea by mentioning how pharmaceutical companies test drug permeability as a potential approach for studying microbial metabolites."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): So Pamela, you work with metabolites and with small molecules. Um, any any thoughts about this? ",
        "annotations": {
            "ask question": "The speaker is requesting information or thoughts from Pamela.",
            "encourage participation": "The speaker is inviting Pamela to contribute her ideas or thoughts."
        }
    },
    {
        "utterance": "Pamela Chang, Cornell: Yeah, so we, I mean in the gut, we look at barrier with uh, uh, you know, either ticker two cells that can form a monolayer and then you can give the trigger and then measure flux with fluorescent molecules of different sizes, but I'm actually not familiar with the blood brain barrier either. ",
        "annotations": {
            "develop idea": "Pamela is expanding on how she and her team study barriers in the gut, describing their methodology.",
            "identify gap": "Pamela explicitly states her lack of familiarity with the blood-brain barrier, identifying a gap in her expertise.",
            "signal expertise": "Pamela mentions her work and expertise in studying gut barriers, showing her familiarity with this area of research."
        }
    },
    {
        "utterance": "Pamela Chang, Cornell: Iyan? ",
        "annotations": {
            "encourage participation": "The speaker is directly addressing Iyan, inviting him to contribute his thoughts or opinions."
        }
    },
    {
        "utterance": "Jilyan Iliev, WCM, Cornell University: Uh, well the the problem is that you have if you do it through the gut brain axis, you have the intestinal barrier and then the blood brain barrier. So it's very hard to model both in an in vitro system. That's why we went for the in vivo system. So we want to see if a defect in one or two is happening and so on. So that's how we couldn't that's why if there is a system to do that in vitro that will be fantastic. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes a limitation in current research methods, specifically the difficulty in modeling both the intestinal and blood-brain barriers in an in vitro system.",
            "develop idea": "The speaker is elaborating on the challenges and considerations in their research approach, developing the idea of why in vivo systems are used and the potential benefits of in vitro systems."
        }
    },
    {
        "utterance": "Andrew Feig (RCSA (he/him)): There's actually an interesting system involving focused ultrasound that you can use to temporarily change the brain uh the CNS barriers. Uh so the blood brain barrier where you can uh the focused ultrasound will cause a temporal gap in the blood brain barrier that allows passage over the span of say 30 seconds and then you can close it again. And so so that would allow you to at least isolate that barrier separate from the intestinal barrier. Um, just a thought. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new method involving focused ultrasound to temporarily change CNS barriers, specifically the blood-brain barrier.",
            "develop idea": "The speaker explains how focused ultrasound can create a temporal gap in the blood-brain barrier, allowing for the isolation of barriers.",
            "offer feedback": "The speaker provides a specific suggestion for a method (focused ultrasound) that could be used in research related to the blood-brain barrier and intestinal barrier."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): So on the intestinal barrier, I'm trying not to talk too much, but I'm just going to mention quickly that the the the paper that I mentioned by Sarkis Mazmanian group Cell 2013, one of the things that they show is that they show that the the the gastrointestinal barrier was uh damage in these mice that had autism like behaviors and that they could repair it with bacterio fragilis. They show that with images of the tissue. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the topic of the intestinal barrier and its relation to behaviors, building upon previous discussions by referencing a specific study."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Faranak? ",
        "annotations": {
            "encourage participation": "Rosa is directly addressing Faranak, inviting her to contribute to the discussion."
        }
    },
    {
        "utterance": "Faranak Fattahi, UCSF: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is too brief and does not explicitly fit any category beyond a basic acknowledgment."
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): Yeah. ",
        "annotations": {
            "None": "No detailed explanation or context is added, and the response is minimal, but it can be considered a supportive response in a minimal form.",
            "supportive response": "The utterance expresses agreement or validation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): And. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a minimal response and does not explicitly fit into any of the provided categories."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Yeah. ",
        "annotations": {
            "None": "No specific code applies as the utterance is a simple acknowledgment"
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): So if I can go back to the metabolites, I know that we we use using chambers to study intestinal physiology, so we can look at ion transport and permeability in pretty good detail. And if you provide certain fatty acids for example, you can improve a disrupted barrier. So metabolites can play a role. Um, with respect to the correlation versus associations, the best one that I know of is IBD where you can measure permeability defects in patients before they become IBD patients if you do a screen. So it suggests that permeability is one of the initiating factors. ",
        "annotations": {
            "develop idea": "Melanie Gareau is expanding on the discussion about metabolites and their role in intestinal physiology and barrier function, providing specific examples.",
            "offer feedback": "She provides specific insights into how certain fatty acids can improve a disrupted barrier, offering a mechanism or potential solution."
        }
    },
    {
        "utterance": "Tom Mansell: and the host aspect is is is not my area of expertise, but I do know that there are biotics that if you when administered, they do create better tight junctions, right? So E coli is an example of uh of a probiotic that um one of its functions of course is to is is niche defense because it's very similar to Shigella and uh salmonella, but um uh another thing that that's been found is in in these kind of monolayer type studies, I not I don't know about in vivo right now, but um you you find increased tight junction formation just from the administration of this this E coli. Um and so the ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of how certain biotics can improve tight junctions, providing an example with E coli.",
            "signal expertise": "The speaker explicitly states that the host aspect is not their area of expertise.",
            "offer feedback": "The speaker provides an example and information about biotics and their effects on tight junctions."
        }
    },
    {
        "utterance": "Tom Mansell: what is the host? So there's, you know, we monitor these things with what E cadherin uh and and other gene expression, right? So um but the actual barrier between cells is uh a sort of mostly protein, mostly extracellular matrix type material, like what is the downstream effect? Like what what we're talking about so far is like what signaling leads to this phenotype, right? But is it is there something about like um the the protein or carbohydrate makeup or availability of those things that may um that may contribute to that and you know, that's that's just I I think about things a lot on the molecular level. So that's that's kind of where I'm sort of coming from here and so if anybody can enlighten me in that respect that would be great. ",
        "annotations": {
            "ask question": "Tom is requesting information or clarification on the molecular level aspects of the barrier between cells.",
            "encourage participation": "Tom is inviting others to contribute their expertise by asking if anybody can enlighten him."
        }
    },
    {
        "utterance": "Faranak Fattahi: are you thinking that some of those components could be affected by the microbiome as well? Like could be directly secreted by them or expressed proteins and the host could be altered by factors from the microbiome? ",
        "annotations": {
            "ask question": "The speaker is requesting information on a prior statement about the potential effects of the microbiome on host components.",
            "develop idea": "The speaker is expanding on a previous topic by asking a clarifying question about the interaction between the microbiome and host components."
        }
    },
    {
        "utterance": "Tom Mansell: Right, so that could be a possible explanation for why short chain fatty acids would do that for example, right? Um as histone deacetylase uh inhibitors. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous idea by suggesting a specific biochemical mechanism (histone deacetylase inhibition) that could explain the effects of short-chain fatty acids."
        }
    },
    {
        "utterance": "Tom Mansell: Um but yeah, I'm I'm really thinking more about the physical makeup of the barrier and is there a you know a nutrient linked um is there something there that's nutrient linked for a bacterium is providing or taking away um an essential building block of of the barrier. ",
        "annotations": {
            "ask question": "Tom is requesting information on whether there's a nutrient link for a bacterium providing or taking away an essential building block of the barrier.",
            "develop idea": "Tom is expanding on the idea of barrier integrity by focusing on the physical makeup and potential nutrient-linked effects by bacteria."
        }
    },
    {
        "utterance": "Tom Mansell: Any ",
        "annotations": {
            "None": "The utterance 'Any ' does not explicitly fit into any of the provided codes as it appears to be an incomplete statement or a prompt for further discussion."
        }
    },
    {
        "utterance": "Tom Mansell: Any ",
        "annotations": {
            "ask question": "Tom Mansell is seeking information or clarification.",
            "encourage participation": "Tom Mansell is inviting further discussion or input."
        }
    },
    {
        "utterance": "Tom Mansell: Any thoughts on that or there particular ",
        "annotations": {
            "ask question": "The speaker is requesting information or thoughts from others.",
            "encourage participation": "The speaker is inviting others to contribute their thoughts or ideas."
        }
    },
    {
        "utterance": "Erin Longbrake: Any ",
        "annotations": {
            "encourage participation": "The speaker is inviting others to contribute their thoughts or ideas, seeking input from the group.",
            "None": "No other code seems to directly apply to this short utterance as it stands, but given its incomplete nature, 'None' might also be considered if only one code is to be chosen. However, based on the context, 'encourage participation' seems most fitting."
        }
    },
    {
        "utterance": "Iliyan Iliev: Any ",
        "annotations": {
            "encourage participation": "The speaker is inviting others to contribute their thoughts or ideas, encouraging participation in the discussion."
        }
    },
    {
        "utterance": "Iliyan Iliev: And it's probably worth also thinking that sorry, sorry, were you Erin, were you ",
        "annotations": {
            "encourage participation": "The speaker invites Erin to contribute by asking 'were you Erin, were you', indicating an attempt to engage Erin in the discussion.",
            "None": "No other code seems to directly apply as the utterance is incomplete and primarily aimed at engaging Erin."
        }
    },
    {
        "utterance": "Erin Longbrake: I was just going to say that something that seems like could be a question that could be studied in an in vitro model system. I don't know the answer though, but it seems like a question that would be amenable to in vitro studies. ",
        "annotations": {
            "ask question": "The speaker is asking if a question could be studied in an in vitro model system, seeking information on research methodology.",
            "develop idea": "The speaker is suggesting a methodological approach (in vitro studies) to explore a research question, building on the previous discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Sorry, the internet kicked me out and it took me a while to be able to get back in. So I hope you guys were doing great without your moderator. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by acknowledging a disruption and rejoicing the group."
        }
    },
    {
        "utterance": "Faranak Fattahi: Just me talking, so no. ",
        "annotations": {
            "Express humor": "The speaker makes a light, humorous comment about their role in the conversation."
        }
    },
    {
        "utterance": "Iliyan Iliev: Oh ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: taking notes. So I we should let give her a chance to talk also because I know she's been busy taking notes. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by suggesting that they give Erin Longbrake a chance to talk.",
            "encourage participation": "The speaker is inviting Erin Longbrake to contribute to the discussion.",
            "acknowledge contribution": "The speaker acknowledges Erin Longbrake's role in taking notes."
        }
    },
    {
        "utterance": "Tom Mansell: Dave, I think you were going to say something there. ",
        "annotations": {
            "encourage participation": "Tom Mansell is inviting Dave to contribute to the discussion, encouraging him to share his thoughts or ideas."
        }
    },
    {
        "utterance": "Dave Durgan: Sorry. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dave Durgan: Oh, I was just going to bring up a more direct interaction, not necessarily metabolites, but active things like proteases like ginger pains and things that can uh at least from the oral bacteria uh have been shown to both break down the epithelium as well as the endothelial barrier uh in brain um so that's more of a a direct protease route which has been shown to have effects at both sites. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea by suggesting a direct interaction mechanism involving proteases from oral bacteria affecting both the epithelium and endothelial barrier in the brain.",
            "develop idea": "The speaker develops the idea by providing specific examples of proteases (like gingipains) and their effects on barriers."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah. So in the gut um um, I don't know if you looked at proteases and fungi because that might be important also. ",
        "annotations": {
            "ask question": "The speaker is requesting information about whether others have looked at proteases and fungi.",
            "propose new idea": "The speaker is introducing proteases and fungi as potentially important factors to consider in the context of gut health and its interaction with the brain."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, we do, we do. We actually have few candidates that that we discovered with uh yeah, human uh human uh antibody assays. ",
        "annotations": {
            "Develop idea": "The speaker expands on previous statements by confirming the existence of candidates discovered using human antibody assays, contributing to the discussion on proteases and fungi.",
            "Supportive response": "The utterance supports the ongoing discussion by providing specific information about the speaker's research findings."
        }
    },
    {
        "utterance": "Iliyan Iliev: Uh and they they are few proteases that are uh you know, that are involved but uh I'm not sure at what level because there are two ways how the barrier, at least two ways, right? How the barrier might be impaired. It can be directly through, you know, tight junction defects and then uh you know, external factors that are uh that are basically aggravating those phenotypes. But then the other problem is actually reparative problems. So those are like very long term uh you know, processes and they can be taking part in specific areas of the intestine. So it's different from the cellular and both of those have have similar effect of uh increased permeability. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by discussing the involvement of proteases in barrier impairment and differentiating between direct impairment, external factors, and reparative problems.",
            "ask question": "The speaker is seeking clarification or further discussion on the level of protease involvement and the differentiation of effects on the barrier."
        }
    },
    {
        "utterance": "Iliyan Iliev: So so so that's how it's very complicated, right? There there is so much uh to do on that side but uh but you know, those two different levels of complication a bit mess up uh the screening approaches because if you start looking at tight junctions, you can set up an in vitro platform and do some part of that with the caveat you don't have immune system there which is very important for this process of basically bringing uh the tight junctions. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous ideas discussed about the complexity of studying the gut-brain axis and its related challenges.",
            "identify gap": "The speaker points out a gap in current research methods, specifically that in vitro platforms lack the immune system, which is important for studying tight junctions."
        }
    },
    {
        "utterance": "Iliyan Iliev: That's a good point though. Um so it sounds ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: That's a good point though. Um so it sounds going back to the original question, it sounds plausible that certain microbes um either make small metabolites that impact the barrier or make proteases that impact components of the barrier. But certainly microbes also impact immune cells which are in the mucosal layers and certainly immune cells have a number of ways to bypass barriers um to migrate into both the brain and other parts of the body to make active metabolites and so you know that one question could be whether the it's a direct effect of um microbes and microbial products or whether the immune cells serve as a as a mediator. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on existing ideas through reasoning and examples.",
            "ask question": "The speaker is requesting information or clarification on a prior statement or idea."
        }
    },
    {
        "utterance": "Iliyan Iliev: And there is one more component actually, toxins. So we just had a study uh there is a fungal toxin that is basically directly uh uh lytic to epithelial cells and microphages underneath. Uh and that is messing up the system a lot and that's not a protease. ",
        "annotations": {
            "propose new idea": "The speaker introduces toxins as an additional component affecting the system.",
            "develop idea": "The speaker elaborates on the effects of a fungal toxin on epithelial cells and microphages.",
            "offer feedback": "The speaker provides specific details about the toxin's mechanism and distinguishes it from proteases."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So how did you how did you find these toxins? Because you were doing proteomics and you found this instead of a protease? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the methodology used to find toxins, comparing it to findings related to proteases.",
            "develop idea": "The question builds upon the previous discussion about proteases and toxins, seeking further clarification."
        }
    },
    {
        "utterance": "Iliyan Iliev: No, it's a huge study. So we started differently. So we first looked at uh patients with IBD where we were looking for specific fungi. So we found actually fungi that are enriched in those specific patients and from there we wanted to see uh if there is any correlation with uh enrichment of those fungi and the disease. And then there wasn't. So we went patient by patient and isolated different strains of uh those fungi and then did genomics and number of different platforms in vitro and that's where actually all those strains, it was a lot of work. So a lot of strains basically split by their ability to damage epithelium or not and they're the same species. So from there we basically took over what is the reason and that's why we went for all the proteases but it wasn't that and then in the genome we found actually this fragment which is responsible for activation of toxin that is process extra cellularly. So so anyway and that toxin though is super potent. Uh and it's actually released in the patients and it correlates with patients that have severe disease, they care carry the strains that produce the toxin. ",
        "annotations": {
            "develop idea": "The speaker is expanding on their research methodology and findings, providing details about their study on fungi and IBD."
        }
    },
    {
        "utterance": "Dave Durgan: slightly in terms of uh the inflammatory response originating from the meninges and then migrating into the brain. Um as we've looked at stroke models more closely, it's not just inflammation in the parenchyma but uh it seems like a large portion of those immune cells are coming from from the meninges and uh it's one of these areas where there's fenestrated uh on the Venus side so it's one of these areas that are very open uh to potentially uh their metabolites or to uh endotoxins things like that coming from uh from the gut. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by sharing specific research findings about the inflammatory response and the role of the meninges in immune cell migration into the brain.",
            "signal expertise": "The speaker implies their expertise through their research findings and discussion."
        }
    },
    {
        "utterance": "Dave Durgan: And there there's just some really interesting observations there. For instance, if you get inflammation and upregulation of IGA in the gut, it also corresponds with increased IGA production uh in the dural layer. Um so it's kind of this coevolutionary idea that it's it's in the benefit of the organism to if something gets across the epithelial barrier to also be able to recognize that at the brain um and respond in a very rapid way, whether that be uh plasma cells which are migrate sensitized in the gut and then migrating to these these areas in the meninges that then have pretty free access to get across to the brain. So kind of an interesting idea. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing knowledge by providing a specific example of how gut inflammation relates to brain responses.",
            "propose new idea": "The speaker introduces a coevolutionary idea as a new perspective on the interaction between gut and brain."
        }
    },
    {
        "utterance": "Iliyan Iliev: But what's the antigen there? That's very interesting. And I I looked at those studies. But what's the antigen in the brain that will activate the plasma cell to keep excreting those IGAs or it's a passive process. ",
        "annotations": {
            "ask question": "The speaker is explicitly asking for information about a specific antigen and its role in activating plasma cells.",
            "None": "No other code explicitly applies to this utterance beyond asking a question."
        }
    },
    {
        "utterance": "Dave Durgan: Well, the I mean the antigens could be coming from either direction, either from there there's circulation to the meninges. and on the Venus side that's where it's highly fenestrated. So you can have antigens from gut entering circulation and then sensitizing these cells in the meninges or you can have like in the case of stroke or brain damage, you can have antigens coming from the parenchyma as well across the meninges and setting off the immune cascade there. ",
        "annotations": {
            "Develop idea": "The speaker is expanding on an existing idea by providing more details about the potential sources of antigens and their pathways to the meninges.",
            "Offer feedback": "The speaker is providing specific ideas about how antigens from the gut could affect the immune response in the brain."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yes, all the migration of IGA plasma blast from the gut going far away, it's very hard to track. We worked a lot on IGA and uh I kind of limit the work actually to the gut because it was very hard to really. ",
        "annotations": {
            "signal expertise": "The speaker shares their experience and work related to IGA, indicating their expertise in the area.",
            "identify gap": "The speaker mentions a challenge they faced in their work, which is tracking the migration of IGA plasma blasts."
        }
    },
    {
        "utterance": "Dave Durgan: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: because IGA plasma blasts are different and they produce uh you know the just monomeric IGA if you if you have antigen going actually systemic and and uh and uh priming them. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a specific idea related to immunology, detailing the behavior of IGA plasma blasts and their production of monomeric IGA in response to antigens."
        }
    },
    {
        "utterance": "Iliyan Iliev: So that's where I don't know what what uh what is the way to track them from the gut to the brain. ",
        "annotations": {
            "ask question": "The speaker is explicitly asking for information or clarification on how to track elements from the gut to the brain.",
            "identify gap": "The speaker is identifying a gap in their knowledge or understanding, specifically on how to track certain elements."
        }
    },
    {
        "utterance": "Dave Durgan: Um all that I can say to that I guess is the evidence that that I'm familiar with is so in the same animal they've uh done B cell receptor sequencing. ",
        "annotations": {
            "Supportive Response": "The speaker is providing evidence they're familiar with to support the discussion.",
            "Signal Expertise": "The speaker is referencing specific scientific methods and their familiarity with evidence, indicating some level of expertise."
        }
    },
    {
        "utterance": "Iliyan Iliev: Oh with BCRs, okay. ",
        "annotations": {
            "code name": "acknowledge contribution",
            "explanation": "The speaker acknowledges another group member's input with a minimal response."
        }
    },
    {
        "utterance": "Dave Durgan: in the in the gut as well as in these areas in the meninges and shown that there's uh very high similarity or cooccurrence of the same receptor uh in both sites that statistically shouldn't be occurring um unless these plasma cells were actually migrating uh from gut to to these meningial areas. ",
        "annotations": {
            "develop idea": "The speaker is discussing and elaborating on research findings related to the interaction between the gut and the meninges, specifically about plasma cells and their migration, building on previous discussions."
        }
    },
    {
        "utterance": "Dave Durgan: So kind of an interesting idea. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive evaluation of an idea discussed, indicating agreement or validation."
        }
    },
    {
        "utterance": "Faranak Fattahi: I have a unrelated question. Um so from the standpoint of developing models that would help the field, um where do you think are like do we have some good ideas around what factors could be triggering the leaky bear like the leaking barriers and we're just trying to drill down on the mechanisms of how that happens or are we in the phase where we're like we should be screening for a larger set of molecules or metabolites or factors that could be coming from the microbiome. I'm trying to think if we need some sort of scalable model in order to search for more of those or models that would help us like, you know, interrogate specific things mechanistically on a more complex level. Uh maybe the answer is both, so I'd love to hear from all of you about that. ",
        "annotations": {
            "ask question": "The speaker is seeking information, thoughts, and opinions from others regarding the current state of research on factors triggering leaky barriers and how to develop models to study this.",
            "clarify goal": "The speaker aims to understand the current stage of research and potential approaches for further investigation, which involves clarifying objectives.",
            "encourage participation": "The speaker invites others to contribute their thoughts, encouraging participation in the discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Don't all speak at the same time. ",
        "annotations": {
            "process management": "This code applies because the speaker is managing the meeting flow by asking participants to avoid speaking simultaneously."
        }
    },
    {
        "utterance": "Tom Mansell: Well, if if we're talking about metabolites, you know, generally we think about metabolites as as organic molecules, right? But a lot of proteases um are are metal dependent, right? So are there bacteria that are I I know for example, um E coli Nissel is um heightens that niche defense because it has a tons of iron transporters. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous ideas by introducing the concept of metal-dependent proteases and questioning about bacteria with specific traits.",
            "ask question": "The speaker is requesting information about the existence of bacteria with certain characteristics, specifically those that have a lot of iron transporters."
        }
    },
    {
        "utterance": "Tom Mansell: basically sucks up all of the iron. And so other organism which is limiting so other organisms are not allowed to use it. Um but zinc and calcium and other, you know, cat ions are often a part of these metallo or matrix metallo proteases. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of how organisms interact through competition for resources like iron and how this relates to metallo proteases.",
            "offer feedback": "The speaker is providing specific information that could be seen as offering feedback on how certain mechanisms work."
        }
    },
    {
        "utterance": "Tom Mansell: Um and so one like even lower than the sort of organic metabolite level is like what's the ion composition um there and is that something that could provide as as as Faranak said uh more mechanistic understanding. Um so things that are secreting siderophores, right? are which which grab and chelate uh ions out of the um out of whatever matrix they're in. ",
        "annotations": {
            "propose new idea": "The speaker introduces considering the ion composition as a factor to understand the system better.",
            "develop idea": "The speaker elaborates on this idea by suggesting it could provide mechanistic understanding, referencing siderophores as an example."
        }
    },
    {
        "utterance": "Tom Mansell: Um thoughts on that anybody? ",
        "annotations": {
            "ask question": "The speaker is explicitly requesting information or thoughts from others.",
            "encourage participation": "The speaker is inviting others to contribute their ideas or perspectives."
        }
    },
    {
        "utterance": "Faranak Fattahi: No. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So are you are you only referring to iron or to any other inorganic molecules? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on Tom Mansell's previous statement regarding whether he is referring to iron or other inorganic molecules.",
            "clarify goal": "The question aims to define or seek clarity on the scope of the discussion, specifically regarding the types of inorganic molecules being considered."
        }
    },
    {
        "utterance": "Tom Mansell: I was just using iron as an example because um uh you know, E Nissel has a bunch of these so therefore and that's how it promotes niche defense. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous point about bacterial competition by providing a specific example of how E. coli Nissle uses iron transporters to promote niche defense."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a prior statement or contribution from another group member."
        }
    },
    {
        "utterance": "Erin Longbrake: So to go back to Faranak's question like what would be a model system to figure out if and how bacteria microbes impact let's just stick with the gut epithelial barrier. you know, barrier function in general. ",
        "annotations": {
            "ask question": "The speaker is requesting information or suggestions on model systems to study the impact of microbes on the gut epithelial barrier.",
            "develop idea": "The speaker is building upon a previous question about model systems to understand microbial impact on barrier function."
        }
    },
    {
        "utterance": "Erin Longbrake: I mean it seems to me like this starts with in vitro experiments with iterative culture systems like you know you have bacteria, you mix bacteria, you you know and then you simplify. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by suggesting a specific methodological approach for studying barrier function."
        }
    },
    {
        "utterance": "Erin Longbrake: That gets a little more complicated because not all bacteria live nicely in culture systems. Um you could also do it with supernants and then try to fractionate the supernants from gut. Um but again, um this seems like an iterative screening process where you have a model system and you iteratively just screen. ",
        "annotations": {
            "Develop idea": "Erin is expanding on the idea of studying bacteria and their effects by suggesting specific methodological approaches.",
            "Offer feedback": "Erin provides suggestions for how to proceed with the research, offering feedback on the methodological approach."
        }
    },
    {
        "utterance": "Faranak Fattahi: Focus on it just. ",
        "annotations": {
            "code name": "process management",
            "explanation": "The speaker is attempting to manage the conversation flow by refocusing attention on a specific point."
        }
    },
    {
        "utterance": "Tom Mansell: proteases, right? So. ",
        "annotations": {
            "offer feedback": "Tom Mansell provides a potential direction by mentioning proteases as possibly relevant to the discussion.",
            "None": "No other codes seem directly applicable as the utterance is brief and does not fully engage with other codes' criteria."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, uh well, some of them, yeah. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a previous statement or contribution, showing awareness and minimal agreement."
        }
    },
    {
        "utterance": "Faranak Fattahi: with the factors or you know the mechanisms are and how they affect the epithelial cells other tissue control rings. You could like imagine multiple layers of in vitro models. You can have a very simple model with just epithelium or like more complex models of gut organoids and then you can have the nerves being there or the immune cells being there and have validation layers then eventually translate all this to mice. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new methodological approach for studying the gut epithelial barrier and its interactions.",
            "develop idea": "The speaker elaborates on the proposed approach, discussing the use of simple and complex in vitro models."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I have not heard much and maybe you guys talked about it when I when I got kicked out about mucose and the mucosal, you know, membrane because that's important too. And that's a source of interaction with microbes. Any comments, thoughts? ",
        "annotations": {
            "Ask Question": "The speaker is seeking information about a topic discussed in her absence, indicating a request for clarification or updates.",
            "Encourage Participation": "The speaker is explicitly inviting others to contribute their thoughts or comments, encouraging participation in the discussion."
        }
    },
    {
        "utterance": "Faranak Fattahi: I mean, would some of these same proteases be involved in mucosal disintegration or like are there ways that microbes could trigger higher production of mucus or is that like, you know, worse for their own survival? I'm not sure just like I don't really know much about the like microbe mucus production cycle if that's something there's much known about that or not. ",
        "annotations": {
            "ask question": "The speaker is asking for clarification or information about the role of proteases in mucosal disintegration and the relationship between microbes and mucus production.",
            "identify gap": "The speaker acknowledges not knowing much about the microbe-mucus production cycle, indicating a gap in their knowledge."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's really important, I think. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and positive evaluation of a previous contribution, indicating that she thinks the point made is really important."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, so they are they are mucinolytic bacteria and and uh are very good examples and you know like uh fungi that we study some of them are actually present in the mucus that's how we figure out actually that they're important for the barrier function. Uh so so uh we still try to figure out if they utilize the mucus uh as a source or they are there for other reasons but for the mucinolytic bacteria is figured out and the enzymes are isolated so that's uh that that's some cool science that has been done there. I I really liked you know the studies from uh uh. ",
        "annotations": {
            "develop idea": "The speaker expands on the concept of mucinolytic bacteria and their role in barrier function.",
            "acknowledge contribution": "The speaker acknowledges related studies, showing awareness of others' work.",
            "supportive response": "The speaker expresses a positive sentiment towards related studies."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Who's left? ",
        "annotations": {
            "encourage participation": "The speaker is encouraging others to participate by asking who's left to speak.",
            "process management": "The speaker is managing the meeting flow by ensuring all voices are heard."
        }
    },
    {
        "utterance": "Iliyan Iliev: Gunnar Gunnar Hansen. He's in uh Sweden. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Do I ",
        "annotations": {
            "ask question": "The speaker is starting to ask a question, seeking information or clarification."
        }
    },
    {
        "utterance": "Iliyan Iliev: I went to one meeting that was very boring and that talk shine and from there it opened another talk. ",
        "annotations": {
            "express humor": "The speaker makes a joke about a past meeting experience, using humor to share a lighthearted moment with the group."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Do any of you know the name or maybe you can put it in the chat? ",
        "annotations": {
            "ask question": "The speaker is requesting information from the group.",
            "encourage participation": "The speaker is inviting others to contribute their knowledge."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: He's uh I think you spell it like that or something here let me see. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So one of the things that got brought up at last year's dialogue meeting was we had there was a bunch of like um engineers who were making things that you ate that went and sampled your gut at multiple locations on all the way down. I almost think that some of thing like this if you could if you could um have that kind of a technological probe that samples mucosal if you will or kind of adherent bacteria um that then you could do sequencing on and kind of target your in vitro screening models to the bugs that you now know are stuck to the mucosa maybe that would be a way to narrow things down a little bit from the entire gut microbiome. I am not a chemist or an engineer in any way but that was something that was brought up a bunch last year. ",
        "annotations": {
            "propose new idea": "The speaker suggests using a technological probe to sample mucosal or adherent bacteria, which is a method to target in vitro screening models to specific bugs in the gut microbiome."
        }
    },
    {
        "utterance": "Iliyan Iliev: No, it's uh it's actually exists that how we found the mucosa associated fungi. So basically all the patients that come for colonoscopy, they go on cleansing so they're clean uh relatively clean and then you go with a scope and you can actually go against the wall and wash from there and take that part and that's where we did the sequencing and that's how we found what's associated with the mucosa but uh in humans it's very hard otherwise. If you go with a probe it's not going to go in the mucosa and sample clean because it will go goes after that in the fecal material. But in mice you can do a lot of cool stuff though. Uh but for humans it's kind of very tricky. We thought about it about two to three years before getting to the right procedure. ",
        "annotations": {
            "develop idea": "The speaker is explaining a research method used to study mucosa-associated fungi, elaborating on how patients are prepared for colonoscopy and how samples are taken for sequencing.",
            "identify gap": "The speaker highlights a challenge in studying mucosa-associated fungi in humans compared to mice, noting it's 'very hard otherwise' and 'kind of very tricky' in humans.",
            "signal expertise": "Iliyan Iliev demonstrates his knowledge of a specific research procedure involving colonoscopy and sequencing to identify mucosa-associated fungi."
        }
    },
    {
        "utterance": "Tom Mansell: that there are on a carbohydrate level, there are some carbohydrate substrates that can be modified um. ",
        "annotations": {
            "offer feedback": "The speaker provides a specific suggestion related to the biochemical modification of carbohydrate substrates, which can be considered a form of feedback to the discussion."
        }
    },
    {
        "utterance": "Tom Mansell: azide groups. So if you have a particular, for example, an O glycan that would be a substrate for a mucinophilic bacteria. Um it's possible that you could synthesize and one of those moieties with a click um substrate on it. So the azide group which enables click chemistry or ligation which would you could then click on a fluorescent probe uh too, right? So um you could those bacteria that are utilizing these things might break it down and then incorporate that into their um you know, proteoglycan. ",
        "annotations": {
            "propose new idea": "The speaker is introducing a new method for studying bacteria and their interaction with substrates.",
            "develop idea": "The speaker is elaborating on the method, including its potential applications and how it could be implemented."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah is there anything like on click chemistry in uh you know, you cannot do that because you cannot express it in the in whole cells. But it will be very cool if you can develop a click chemistry that actually the human cell is producing half of of the azide, right? And then you add the probe. That will be very cool. ",
        "annotations": {
            "propose new idea": "Iliyan Iliev introduces a new idea of developing a click chemistry system where human cells produce part of the necessary components.",
            "develop idea": "He elaborates on the idea by discussing its potential and current limitations.",
            "ask question": "Iliyan Iliev asks if there is anything like the proposed click chemistry system, showing he is seeking information."
        }
    },
    {
        "utterance": "Tom Mansell: Oh, that's that chemistry sounds pretty hard to do in vivo. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: It's very hard. Yeah, yeah, yeah. That but that's that's the dream actually to do it. Otherwise with the substrate it's very cool as well but uh. ",
        "annotations": {
            "supportive response": "Iliyan expresses agreement and a positive sentiment towards an idea or method.",
            "identify gap": "Iliyan mentions that something is 'very hard', implying a challenge or gap."
        }
    },
    {
        "utterance": "Tom Mansell: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Yeah. ",
        "annotations": {
            "None": "The utterance is a brief expression of agreement without adding new content."
        }
    },
    {
        "utterance": "Pamela Chang: Sorry, so I was a PhD student in Carolyn's lab and that was part of my PhD thesis. So actually since I left the lab uh the number of studies have come out from other groups that have been able to do that in vivo labeling in in in a mouse. Um and in some cases they can even do the click chemistry in vivo too. Uh if you're interested I can send you send you some uh some of those papers but but yeah, I'm I sorry I didn't mention I'm trained as a chemist my PhD and then I went to immunology. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her background as a chemist with a PhD and her transition to immunology, signaling her expertise."
        }
    },
    {
        "utterance": "Tom Mansell: I'd be really interested in that um for sure. ",
        "annotations": {
            "Supportive response": "The utterance expresses interest and is a positive response to an offer, indicating agreement and validation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So we have about another 15 minutes and then it might be a good idea to look at um to maybe have Erin share her screen so we can summarize highlights and see what we're going to report. Um so I'm I'm I'm I'm happy to let you know in like 10 or 15 minutes but I just wanted to bring to your attention that maybe um if there's something you really wanted to say and you haven't brought it up, maybe this is a good time. ",
        "annotations": {
            "process management": "The speaker is managing the meeting's flow and time.",
            "summarize conversation": "The speaker is suggesting a summary of highlights.",
            "encourage participation": "The speaker is inviting others to contribute if they have something to add."
        }
    },
    {
        "utterance": "Faranak Fattahi: I have no specific thoughts, but I do have a question. I I wondered if Melanie could tell us a little bit more about the assays you do to measure epithelial barrier. We talked about um fluxing chambers and um so how how high throughput are they and like can you like, you know, test 100 things or is it like only a matter of a few things that you can evaluate in them? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the assays used to measure the epithelial barrier, specifically asking about the throughput of fluxing chambers."
        }
    },
    {
        "utterance": "Melanie Gareau: Sure. Um so chambers are great at getting lots of information on not so many samples. Um so they're not very high throughput. We have eight right now um to do a fitC assay, it's a two hour assay, so you can only do eight times two, maybe three in a day, so it's low throughput. ",
        "annotations": {
            "signal expertise": "The speaker is explicitly stating her knowledge and experience with the assay, providing detailed information about its limitations and capabilities."
        }
    },
    {
        "utterance": "Melanie Gareau: Um but you get a lot of information um so we can really get at the pathway whether it's transcellular, um uh paracellular, um when you modify the chambers you can actually get at whether enteric nerves are contributing to it because they're still intact in there. Um so it's they're really powerful but they're very low throughput. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the use of chambers for studying intestinal barrier function, detailing how they provide insights into pathways and enteric nerve contributions.",
            "offer feedback": "The speaker is providing specific feedback on the methodology of using chambers, discussing their power for detailed analysis and their limitation in throughput."
        }
    },
    {
        "utterance": "Faranak Fattahi: Um so that's one of the big problems. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Melanie Gareau: We can put organoids on them so we don't we haven't done it yet, but I know that you can so you can put inserts in in there. ",
        "annotations": {
            "develop idea": "The speaker is discussing how to implement a methodological approach, specifically using organoids on inserts, which expands on existing ideas of experimental design."
        }
    },
    {
        "utterance": "Melanie Gareau: Um there so you you can get more information than for example um TER for uh Kiko tubes or something like that. Um so so and we can also do in vitro stimulation. So you can you can put molecules in there, watch them transport across or see how they interact and generate or change ion transport or permeability. ",
        "annotations": {
            "Develop idea": "The speaker is elaborating on the capabilities of using chambers for experiments, including in vitro stimulation.",
            "Signal expertise": "The speaker is demonstrating her expertise in experimental methods related to epithelial barriers."
        }
    },
    {
        "utterance": "Melanie Gareau: So we've done that as well. Um it it's the throughput problem. So you really need to know what you're you have to narrow it down um before you set it up. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous point about the limitations of their assay method, specifically discussing the throughput problem and the need to narrow down what to test before setting up the assay."
        }
    },
    {
        "utterance": "Faranak Fattahi: Are there like markers? I'm thinking if there are if you have like a section of the epithelium or just like an epithelial monolayer culture, are there proxies or markers that correlate with epithelial integrity that you could use for a higher throughput and maybe image-based analysis or some other indirect way of correlating that with barrier integrity to then first cast the wide net and then narrow things down for these more sophisticated measurements. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the existence of markers that could be used to assess epithelial integrity in a higher throughput manner."
        }
    },
    {
        "utterance": "Melanie Gareau: Not a reliable one that I could think of. Um I'd have to maybe go back and look a little bit more closely, but to my knowledge there isn't one really reliable factor. There's a few that have kind of come up and then we're kind of disregarded. Um I think there's more a lot of movement towards uh co-culture systems with um more engineering involved where you have small wells that are separating cells um to kind of create gut brain models that way. So I that's not something that I know much about, but that's certainly where people are going with um collaborating epithelial physiologist collaborating with um engineers and things like that. So there I know there's a lot of people that are creating uh in vitro compartmentalized systems where you can compare those things, those would be higher throughput. ",
        "annotations": {
            "identify gap": "Melanie Gareau explicitly states that to her knowledge, there isn't a really reliable factor for assessing epithelial integrity.",
            "develop idea": "She elaborates on current trends and future directions in the field, discussing co-culture systems and in vitro compartmentalized systems."
        }
    },
    {
        "utterance": "Tom Mansell: Hey, would you mind putting the name of this uh device in the chat? I'm going to so I know how to spell it. ",
        "annotations": {
            "ask question": "The speaker is requesting information or action from others, which is a form of questioning."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, I caught chambers but not. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, yeah. Okay, great. ",
        "annotations": {
            "Supportive response": "Expressing agreement and positive evaluation for previous statements."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So what I'm hearing from you Melanie is that um these are great to test specific hypothesis, which is what you do with a lower throughput system. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing their understanding of a previous discussion about the use of certain methods for testing specific hypotheses."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You know, I think people that think about higher throughput system is more to do stuff that I would say it's maybe more exploratory. Um which is great, you know, to generate hypothesis, but it sounds like your systems are good to test specific hypothesis. Is that am I hearing that right? ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing the discussion about the use of higher throughput systems for exploratory purposes versus testing specific hypotheses.",
            "clarify goal": "The speaker is seeking clarity on the goals and uses of different systems discussed in the meeting.",
            "ask question": "The speaker ends the utterance with a question seeking confirmation of her understanding."
        }
    },
    {
        "utterance": "Melanie Gareau: Yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You know, do you want to share Erin? I hope you can share so we can all make sure that um your contributions are all there. ",
        "annotations": {
            "encourage participation": "The speaker invites Erin to contribute by sharing, encouraging her participation in the discussion or meeting."
        }
    },
    {
        "utterance": "Erin Longbrake: Um it looks like I can give me one second to find the right window. Okay, here we go. ",
        "annotations": {
            "process management": "Erin Longbrake is managing the meeting flow by preparing to share her screen."
        }
    },
    {
        "utterance": "Erin Longbrake: Erin Longbrake (Yale) has started screen sharing ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Is this how they want us to share it? ",
        "annotations": {
            "process management": "The speaker is asking for confirmation on the procedure for sharing a document or screen, which is related to managing the meeting flow."
        }
    },
    {
        "utterance": "Erin Longbrake: Because last year they actually had a a slide, a PowerPoint slide. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Faranak Fattahi: Right, I think we need to copy this over to the PowerPoint deck. I think it's also in the same Google Drive. ",
        "annotations": {
            "process management": "The speaker is suggesting an action to organize meeting materials by copying content to a PowerPoint deck and checking its availability in Google Drive."
        }
    },
    {
        "utterance": "Erin Longbrake: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So that's something that maybe we can do. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement and a positive evaluation regarding an action item, indicating a willingness to consider or act on a suggestion."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, this one. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, that one. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging or agreeing with something previously said or shown."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: idea though is to have just a couple points. We wanted to still our discussion to. ",
        "annotations": {
            "propose new idea": "The speaker introduces a suggestion about focusing on a couple of points for discussion.",
            "develop idea": "The speaker builds upon previous thoughts about discussion objectives.",
            "process management": "The utterance helps in managing the discussion flow by suggesting to focus on a couple of points."
        }
    },
    {
        "utterance": "Erin Longbrake: Points that are shareable. ",
        "annotations": {
            "summarize conversation": "Erin Longbrake is contributing to summarizing the discussion by mentioning points that are shareable, indicating an effort to consolidate and report key discussion points.",
            "process management": "This utterance also reflects an aspect of process management as Erin Longbrake is helping to organize and direct the discussion towards a summary of key points."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, exactly. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with a prior statement, indicating a positive evaluation without adding new content."
        }
    },
    {
        "utterance": "Erin Longbrake: All right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: We can talk about if they're linked or correlated, but that's fine. ",
        "annotations": {
            "supportive response": "Erin is showing a positive attitude towards discussing the topics, indicating a willingness to engage."
        }
    },
    {
        "utterance": "Erin Longbrake: Okay, so there was a fair amount of discussion about the various pieces of things that could be impactful and direct versus indirect effects of gut microbes, soluble metabolites, proteases, effects on immune cells and then subsequent immune cell effects on so I think that was one common theme. ",
        "annotations": {
            "summarize conversation": "Erin Longbrake is summarizing the discussion about the effects of gut microbes, soluble metabolites, proteases, and immune cells."
        }
    },
    {
        "utterance": "Erin Longbrake: Um. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: There was some talk about two different barrier functions, the gut epithelial barrier and the blood brain barrier is potentially both being important to understand separately and the likelihood of multi-hit hypothesis um being necessary to open them all. Um Tom brought up some interesting points about molecular structures and the how the tight junctions were functioning and whether bacteria could change the composition of tight junctions um or add or subtract some key component of the epithelial barrier. ",
        "annotations": {
            "summarize conversation": "The speaker summarizes previous discussion points about barrier functions and the potential for a multi-hit hypothesis.",
            "develop idea": "The speaker also elaborates on existing ideas by mentioning specific points discussed, such as the role of molecular structures and tight junctions."
        }
    },
    {
        "utterance": "Erin Longbrake: And then the I discussion. Yeah, inorganic chemistry I would call it. But yes, you can call it ion discussion. Yeah. And then the discussion about model systems and we didn't have a good answer for a high throughput screening system, but it seemed like that was what would be needed to tease it out and break it apart was a first a high throughput screening system. ",
        "annotations": {
            "summarize conversation": "The speaker reflects on previous discussions and highlights the need for a high-throughput screening system, effectively summarizing the conversation's current state and future direction."
        }
    },
    {
        "utterance": "Erin Longbrake: And then iteratively more complicated methods. ",
        "annotations": {
            "summarize conversation": "The utterance attempts to summarize a part of the conversation regarding methodologies."
        }
    },
    {
        "utterance": "Erin Longbrake: Um and we had talked about engineering models to in human sample bugs from different anatomic regions or locations within the lumen versus the mucosa and then in mice using different parts of the intestinal tract in the using chamber model system to study specific effects, but it being necessary to do a fair amount of preliminary high throughput work to get your hypothesis to study in the more detailed model system. I don't know. ",
        "annotations": {
            "develop idea": "Expanding on previous discussions about engineering models for studying bugs from different anatomic regions.",
            "summarize conversation": "Summarizing previous discussions on models and the necessity of high-throughput screening.",
            "process management": "Discussing methodological approaches for studying specific effects."
        }
    },
    {
        "utterance": "Erin Longbrake: That's what I'm pulling out. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's good. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation with the previous contribution, indicating a positive evaluation without adding new content."
        }
    },
    {
        "utterance": "Erin Longbrake: I just have to recapitulate it again. Hold on. ",
        "annotations": {
            "process management": "Erin Longbrake is managing the discussion flow by asking to recapitulate previous information to ensure clarity or understanding among participants."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: interactive, please speak up also if you see something missing. ",
        "annotations": {
            "encourage participation": "The speaker is inviting others to contribute to the discussion, especially if they see something missing."
        }
    },
    {
        "utterance": "Erin Longbrake: Yes, please. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a simple acknowledgment or agreement without adding new content."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Sorry, I'm eating as you write because I'm going to have to run to teach right after we close. So if I don't eat now, I won't eat in like three hours. ",
        "annotations": {
            "process management": "The speaker is managing her time and participation in the meeting by mentioning her need to eat before leaving to teach."
        }
    },
    {
        "utterance": "Erin Longbrake: Of course. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or acknowledgment to a previous statement or request."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And and you're you're writing there need for high throughput screening, but maybe we can also add a bullet point of there are some lower throughput screening methods that might be good to test specific hypothesis, but we need to get there. We need to know which specific hypothesis. We want to be testing. What do you guys think? ",
        "annotations": {
            "develop idea": "The speaker builds upon the previous discussion about high throughput screening by suggesting also to consider lower throughput screening methods for testing specific hypotheses.",
            "encourage participation": "The speaker invites the group's thoughts with 'What do you guys think?', encouraging participation.",
            "process management": "The speaker guides the discussion by suggesting how to approach the methodology, emphasizing the need for specific hypotheses."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Feel free to correct it or add something else. I'm just trying to get other people help Erin. ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute by suggesting they can correct or add to what Erin has written.",
            "supportive response": "The speaker is trying to facilitate help for Erin, showing a supportive attitude.",
            "process management": "The speaker is managing how the group contributes to Erin's task by inviting input."
        }
    },
    {
        "utterance": "Melanie Gareau: Erin, it's oozing with ing, not AR, I just noticed. ",
        "annotations": {
            "express humor": "The speaker is making a lighthearted comment to correct someone, which can be interpreted as an attempt to express humor."
        }
    },
    {
        "utterance": "Erin Longbrake: Okay, thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Has anybody here been gotten successfully funded by the bylog? ",
        "annotations": {
            "ask question": "The speaker is requesting information from other group members about their experiences with being funded by a specific entity, 'the bylog'."
        }
    },
    {
        "utterance": "Erin Longbrake: I didn't last year. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: we didn't either. ",
        "annotations": {
            "supportive response": "The speaker is expressing alignment with a previous statement about not getting funded.",
            "acknowledge contribution": "The speaker is also acknowledging the previous speaker's statement."
        }
    },
    {
        "utterance": "Tom Mansell: I I have a grant. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it seems to be a simple statement of fact or an attempt to share personal information without clear connection to the discussion at hand."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I know I know someone at ASU that got funded last year by the way. Habishek, I don't know if you met him last year. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dave Durgan: partner on that. ",
        "annotations": {
            "acknowledge contribution": "Dave Durgan is acknowledging someone's involvement or association with a project that received funding."
        }
    },
    {
        "utterance": "Tom Mansell: Okay, there you go. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: I'm just thinking that for their purposes, like so, you would think that, okay, so if you go to NIH with this idea, right? If you're talking about high throughput high throughput screens, immediately a reviewer says this is a fishing expedition. This is hypothesis generating, go somewhere else, right? Do you think that these guys are keen to fund that kind of thing or like hypothesis generation, which will be too risky for NIH, or do you think that they're more translationally focused on that. ",
        "annotations": {
            "ask question": "The speaker is asking a question about the funding priorities of a group.",
            "clarify goal": "The speaker is seeking clarity on the goals or priorities of a funding body."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: There's a on the high risk high yield, I thought. ",
        "annotations": {
            "process management": "The speaker is referring to a funding opportunity or program described as 'high risk high yield', which relates to managing research projects or initiatives."
        }
    },
    {
        "utterance": "Tom Mansell: High risk high yield, right? So it's. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it is more of a reflective comment."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah. So I I confess I was invited to be part of the review panel last year, but I wasn't. So I wish I had been there so I could give you an answer of like what the panel was actually looking for. We didn't get a lot of feedback either, so that was. The and I I can you can provide that on your surveys as a comment that it would be helpful to get some feedback on your proposal so they know what you're they're looking for, right? And I can provide that too since I heard it from you, but my guess is that the the idea of this is to get funding that NIH wouldn't fund funded, you know, or get you started. ",
        "annotations": {
            "process management": "The speaker is discussing the process of funding and the importance of feedback on proposals.",
            "offer feedback": "The speaker is offering to provide feedback on proposals.",
            "clarify goal": "The speaker is discussing the goal or purpose of the funding."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, it's it's really crazy. I I had like two grants not discussed there. It's a cell paper. It's just ridiculous. ",
        "annotations": {
            "critical response": "The speaker is expressing frustration and criticism towards the grant discussion process, finding it ridiculous that two grants, one of which was published in Cell, were not discussed."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Anyway, so. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So so those are the mechanisms here, yeah. one one comment that I want to make especially to junior faculty is that not funded by NIH does not mean that it's not good research and it doesn't mean that it's not promising research. NIH NIH chose not to fund the production of insulin through genetic engineering the way it's done, you know, because it it was too risky to blah blah blah. So the the investigator that proposed that got completely rejected and that's the way that insulin is produced in, you know, for everyone nowadays. So there are many great ideas that don't go through NIH and I'm not saying don't go to NIH and I'm not saying, you know, don't try, but I I what I'm saying is that if you know it's a good idea, pursue it through other ways or pursue getting preliminary data so you can show that to NIH. That's that's my advice here, you know, my mentoring advice. ",
        "annotations": {
            "Offer feedback": "The speaker is providing advice and feedback to junior faculty on how to handle not being funded by NIH and suggesting alternative paths for their research.",
            "Encourage participation": "The speaker encourages junior faculty to pursue their research ideas through other means if they are not funded by NIH.",
            "Process management": "The speaker is guiding the discussion towards a positive and encouraging note for junior faculty."
        }
    },
    {
        "utterance": "Pamela Chang: Are there other, sorry, this is getting a little off topic, but are there other foundations that would be interested in funding gut microbiome research because I had a similar experience with NIH. I don't know if anyone else found alternatives. I mean, aside fromlog. ",
        "annotations": {
            "ask question": "Requesting information from other team members on funding sources for gut microbiome research."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I I would say, um, my with my knowledge and my experience because there might be others, they're more like disease specific. So I've gotten I've gotten funding from Autism Research Institute and Autism Speaks. They're more to the disorder that you're targeting. And and and I also want to mention because I'm a reviewer at NIH that one of the challenges at NIH is that right now microbiome is everywhere. So what they do is you send a proposal that has some microbiome component, they send it to a panel that is investigating, I'm going to put aging as an example, okay? So aging and the microbiome. So they send it to an aging panel where no one there knows about the microbiome, but they call someone like Rosie to be the microbiome expert. And no matter how much Rosie likes that proposal, there's other reviewers that don't maybe don't appreciate the value of the microbiome. So unless Rosie is super outspoken and super defense that proposal and super able to articulate the importance of the microbiome there, the proposal will not get funded. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her role as a reviewer at NIH and shares her experience.",
            "offer feedback": "The speaker is providing insights and advice based on her experience with funding and reviewing proposals."
        }
    },
    {
        "utterance": "Iliyan Iliev: And especially if you end up in a study section when, you know, they're already established for a long time, if it goes to brain study section, you come with immunologist, what are you talking about? We study circuits here, you're dead. So. ",
        "annotations": {
            "Critical response": "The speaker is critiquing the current system of study sections, particularly how research from different fields (immunology vs. brain study) might be received, expressing skepticism and concern about the potential dismissal of interdisciplinary research."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And and I'm telling you honestly because I've been called to so many of these panels in the last two, three, four years that I've tried very hard to find the value on the microbiome, especially when it's good work and to try to defend it, but it doesn't always work, you know? So, um, yeah. And so one thing that I see in the microbiome world that it's really important is that we we raise each other, especially with good science, you know, and we defend each other because that's really important. Uh, but of course that you do good science because otherwise nothing's going to proceed, but I I'm sure you guys are here because you do good science, otherwise you wouldn't even have been invited. ",
        "annotations": {
            "encourage participation": "Rosa Krajmalnik-Brown encourages the community to support each other, especially with good science.",
            "process management": "Her encouragement can also be seen as a way to positively manage the group's dynamics."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, I mean the institution I'm right now, they're very supportive to that one time it will fly, but I was in another institution and I brought a grant that just gave like 5% or something and they asked me to find another 45% to pay to the institution. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, so it depends on the institution as well, yeah. ",
        "annotations": {
            "supportive response": "The speaker is providing a supportive and agreeable response, acknowledging the variability in institutional support for research."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You have the can, the can then move iteratively or you want you want it there. Can. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Are you guys happy with our report slide just to. ",
        "annotations": {
            "ask question": "The speaker is seeking feedback or opinion on the report slide."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Sorry, Erin. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: No, no, no. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, amazing. Thanks a lot for doing that. ",
        "annotations": {
            "acknowledge contribution": "The speaker is thanking and acknowledging Erin Longbrake's effort in summarizing the discussion points.",
            "supportive response": "The speaker is expressing a positive sentiment towards the summary or the effort made."
        }
    },
    {
        "utterance": "Erin Longbrake: I'm going to go back to that for two minutes to make sure this isn't just me making stuff up. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Right. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with the previous statement."
        }
    },
    {
        "utterance": "Iliyan Iliev: So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Some institutes are more open. Some institutes will say like, you know, as long as you're doing good work and the money eventually comes in anyhow, right? Because that money is coming in for me to pay postdocs and for me to pay supplies and it has to come into the institution. You're absolutely right and I did it as a full professor. I don't know that this works for an assistant professor. Like I agree with you, you know? ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, I mean the institution I'm right now, they're very supportive to that one time it will fly, but I was in another institution and I brought a grant that just gave like 5% or something and they asked me to find another 45% to pay to the institution. So so yeah, so it depends on the institution as well, yeah. ",
        "annotations": {
            "supportive response": "The speaker shares a personal anecdote about institutional support for grant funding in a supportive manner."
        }
    },
    {
        "utterance": "Erin Longbrake: Where do you want it? You want it over there? ",
        "annotations": {
            "ask question": "Erin is asking for clarification on the placement of something.",
            "process management": "The question relates to organizing or arranging something in the meeting context."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I don't know. I'm asking you if you wanted if if it was there on purpose. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: It was supposed to be a bullet point under the one above, but it didn't format the way I thought it was going to. ",
        "annotations": {
            "process management": "The speaker is discussing an issue with the formatting of a bullet point in a shared document, which relates to managing the organization of their discussion and documentation process."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Oh, okay. Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unidentified Speaker: Yeah, yeah. ",
        "annotations": {
            "confirm decision": "No decision is confirmed."
        }
    },
    {
        "utterance": "Erin Longbrake: Is there anything additionally that I just big talk picks that I neglected to put on here? ",
        "annotations": {
            "ask question": "The speaker is requesting information about additional points that might have been neglected."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think um we mentioned fun size at some point and I don't I don't see it anywhere. I don't know if we want to call it out or not. ",
        "annotations": {
            "process management": "The speaker is discussing how to handle a potentially missed point in their conversation, indicating an effort to manage the meeting's flow and ensure all relevant topics are covered."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, there you go. Thank you. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges and thanks another group member for their input or action."
        }
    },
    {
        "utterance": "Erin Longbrake: All right. If you guys are happy with that, we can go back to the funding discussion, which is probably more high yield anyway. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by suggesting a transition to discuss funding."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Are you guys okay with that? Are you all okay with that? ",
        "annotations": {
            "confirm decision": "The speaker is seeking confirmation or agreement from the group on a previous statement or proposal."
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I'm sorry, I didn't mean to divert the I was just trying to answer and help Tom. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: No, it was a high yield discussion and one that's definitely valuable. I just wanted to before we got dumped out, make sure that I was appropriately group centered on what I was reporting back. ",
        "annotations": {
            "Supportive response": "Erin is expressing agreement and positive evaluation of the discussion.",
            "Acknowledge contribution": "Erin is acknowledging the value of the discussion and her intention to report back appropriately.",
            "Process management": "Erin is commenting on her process of ensuring her report is centered on the group's contributions."
        }
    },
    {
        "utterance": "Erin Longbrake: Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: NIH is really difficult. I just um yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: They don't like funding anything that's risky and there's a bias towards hypothesis. I I I don't fully buy into this like has to be hypothesis generated research. There's so much that we don't know you have to do observations before you can generate a hypothesis. So who's going to fund the observations? ",
        "annotations": {
            "Ask question": "Erin asks a question about who will fund observations.",
            "Identify gap": "Erin implies a gap in funding for observational research.",
            "Critical response": "Erin critiques the bias towards funding hypothesis-driven research."
        }
    },
    {
        "utterance": "Faranak Fattahi: Startup package. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, I mean it just seems it seems ridiculous. ",
        "annotations": {
            "critical response": "The speaker is expressing a negative sentiment towards the current situation, implying that it is unreasonable or unjust, which aligns with a critical response."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: And and barrier inducing. So I don't know. There seems at least in my institution, there's a fair amount of um snobbery when it comes to being NIH funded versus not NIH funded. And I have a fair amount of pharma funding right now, which is good for me, but doesn't have the same cachet for promotion and tenure or whatever. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's the thing that for promotion and tenure if you have an R01, it speaks volumes. ",
        "annotations": {
            "clarify goal": "Rosa Krajmalnik-Brown clarifies the importance of having an R01 grant for promotion and tenure in academia, highlighting it as a significant goal for researchers."
        }
    },
    {
        "utterance": "Tom Mansell: Maybe shouldn't. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: We're about we're about to be kicked out. I think Dave wanted to say something before we get kicked out. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow, indicating they are about to conclude and wants to allow another participant to contribute before they are 'kicked out'."
        }
    },
    {
        "utterance": "Tom Mansell: No, this has been great. ",
        "annotations": {
            "supportive response": "Tom Mansell is expressing a positive sentiment about the discussion, indicating it has been great."
        }
    },
    {
        "utterance": "Unidentified Speaker: Yeah, that was a great discussion. ",
        "annotations": {
            "Supportive response": "The speaker is expressing a positive evaluation of the discussion."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation for other group members' contributions without adding new content."
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah, thank you all. Thank you Aaron for putting the slides together. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges Aaron's contribution in putting the slides together.",
            "supportive response": "The speaker expresses gratitude to all and specifically to Aaron, showing a positive and supportive attitude."
        }
    },
    {
        "utterance": "Unidentified Speaker: Thanks for reporting. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, thank you, Erin. ",
        "annotations": {
            "acknowledge contribution": "Tom Mansell verbally recognizes Erin Longbrake's input by thanking her."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you. I'm sorry I got kicked out in the middle. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unidentified Speaker: You were you were back fast. It was good. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Um on the NIH, keep on pursuing it and talk to program directors. That's my advice because I I actually have two R1s funded and it wouldn't have happened if I hadn't talked to program directors and pursuing it and keep keep on trying, make it better, talk to program directors. That's my advice. ",
        "annotations": {
            "signal expertise": "Rosa Krajmalnik-Brown shares her personal experience of having two R01s funded to establish credibility.",
            "supportive response": "The utterance is supportive, offering advice and encouragement to others in the group.",
            "offer feedback": "Rosa Krajmalnik-Brown offers feedback based on her personal experience with NIH funding."
        }
    },
    {
        "utterance": "Tom Mansell: All right, thanks everyone. ",
        "annotations": {
            "supportive response": "Expressing agreement, validation, or positive evaluation for the discussion or meeting."
        }
    },
    {
        "utterance": "Unidentified Speaker: Thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Richard Wiener: Welcome back everyone. Uh is there anyone still working to get their notes into the PowerPoint? ",
        "annotations": {
            "process management": "Managing meeting flow, specifically checking if anyone still needs to work on getting their notes into the PowerPoint."
        }
    },
    {
        "utterance": "Stephanie Cologna: I think our team could use like one more minute. ",
        "annotations": {
            "process management": "The speaker is requesting more time for her team, which is an act of managing the meeting flow and time."
        }
    },
    {
        "utterance": "Richard Wiener: All right, we'll give one more minute. We'll what we'll do for the report out is we'll just go to each room and ask the ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow, deciding to give participants one more minute before proceeding with the report out."
        }
    }
]